Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Ilaina Monroe"'
Autor:
Shuchi Gulati, McKenzie Crist, Muhammed Kashif Riaz, Vinita Takiar, Maria Lehn, Ilaina Monroe, Sarah Palackdharry, Nicky Kurtzweil, Roman Jandarov, Nusrat Harun, Trisha M. Wise-Draper
Publikováno v:
Clinical Cancer Research. 29:1906-1915
Purpose: The efficacy of cetuximab is poor in metastatic head and neck squamous cell carcinoma (HNSCC). Cetuximab initiates natural killer (NK) cell–mediated antibody-dependent cellular cytotoxicity, with resultant recruitment of immune cells and s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e11ca4d9b145a4397a99c9e932feecf6
https://doi.org/10.1158/1078-0432.ccr-22-3886
https://doi.org/10.1158/1078-0432.ccr-22-3886
Autor:
Trisha M. Wise-Draper, Nusrat Harun, Roman Jandarov, Nicky Kurtzweil, Sarah Palackdharry, Ilaina Monroe, Maria Lehn, Vinita Takiar, Muhammed Kashif Riaz, McKenzie Crist, Shuchi Gulati
Supplementary Figure 5. Comparison of outcomes between patients that were PD-L1 positive vs. negative A) Progression-free survival and B) Overall survival comparison
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dd83873a53f1a42ff782129d01f3f7c
https://doi.org/10.1158/1078-0432.22820213.v1
https://doi.org/10.1158/1078-0432.22820213.v1
Autor:
Trisha M. Wise-Draper, Nusrat Harun, Roman Jandarov, Nicky Kurtzweil, Sarah Palackdharry, Ilaina Monroe, Maria Lehn, Vinita Takiar, Muhammed Kashif Riaz, McKenzie Crist, Shuchi Gulati
Purpose:The efficacy of cetuximab is poor in metastatic head and neck squamous cell carcinoma (HNSCC). Cetuximab initiates natural killer (NK) cell–mediated antibody-dependent cellular cytotoxicity, with resultant recruitment of immune cells and su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68e81948eec90641746a5c3899a11cf5
https://doi.org/10.1158/1078-0432.c.6489320
https://doi.org/10.1158/1078-0432.c.6489320
Autor:
Trisha M. Wise-Draper, Nusrat Harun, Roman Jandarov, Nicky Kurtzweil, Sarah Palackdharry, Ilaina Monroe, Maria Lehn, Vinita Takiar, Muhammed Kashif Riaz, McKenzie Crist, Shuchi Gulati
All adverse events on trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34e0aa90cc85948dcc276e4386dfe832
https://doi.org/10.1158/1078-0432.22820198
https://doi.org/10.1158/1078-0432.22820198
Autor:
Trisha M. Wise-Draper, Nusrat Harun, Roman Jandarov, Nicky Kurtzweil, Sarah Palackdharry, Ilaina Monroe, Maria Lehn, Vinita Takiar, Muhammed Kashif Riaz, McKenzie Crist, Shuchi Gulati
Representativeness of Study Participants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ace9458db41be423afea6259c8f1d9c
https://doi.org/10.1158/1078-0432.22820189.v1
https://doi.org/10.1158/1078-0432.22820189.v1
Autor:
Trisha M. Wise-Draper, Nusrat Harun, Roman Jandarov, Nicky Kurtzweil, Sarah Palackdharry, Ilaina Monroe, Maria Lehn, Vinita Takiar, Muhammed Kashif Riaz, McKenzie Crist, Shuchi Gulati
Consort diagram of the clinical trial.Abbreviations: OS, overall survival; PFS, progression-free survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::115807b0773e0f8af977fbb034d07d3e
https://doi.org/10.1158/1078-0432.22820222
https://doi.org/10.1158/1078-0432.22820222
Autor:
Trisha M. Wise-Draper, Nusrat Harun, Roman Jandarov, Nicky Kurtzweil, Sarah Palackdharry, Ilaina Monroe, Maria Lehn, Vinita Takiar, Muhammed Kashif Riaz, McKenzie Crist, Shuchi Gulati
All treatment-related adverse events on trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::235d8f8fa6cef7b9a60ceaac2e9540ca
https://doi.org/10.1158/1078-0432.22820192.v1
https://doi.org/10.1158/1078-0432.22820192.v1
Autor:
Trisha M. Wise-Draper, Nusrat Harun, Roman Jandarov, Nicky Kurtzweil, Sarah Palackdharry, Ilaina Monroe, Maria Lehn, Vinita Takiar, Muhammed Kashif Riaz, McKenzie Crist, Shuchi Gulati
Study Schema. This is a single-arm, phase II trial combining durvalumab and cetuximab in patients with recurrent/metastatic HNSCC. Patients received the loading dose of cetuximab followed by the addition of durvalumab with weekly cetuximab doses. CT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d11cdc371e27ba063643c86aae2f4b6
https://doi.org/10.1158/1078-0432.22820225
https://doi.org/10.1158/1078-0432.22820225
Autor:
Trisha M. Wise-Draper, Nusrat Harun, Roman Jandarov, Nicky Kurtzweil, Sarah Palackdharry, Ilaina Monroe, Maria Lehn, Vinita Takiar, Muhammed Kashif Riaz, McKenzie Crist, Shuchi Gulati
Study protocol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a26c5e959e559bfdaa862cc7f9ce2adf
https://doi.org/10.1158/1078-0432.22551876.v1
https://doi.org/10.1158/1078-0432.22551876.v1
Autor:
Trisha M. Wise-Draper, Nusrat Harun, Roman Jandarov, Nicky Kurtzweil, Sarah Palackdharry, Ilaina Monroe, Maria Lehn, Vinita Takiar, Muhammed Kashif Riaz, McKenzie Crist, Shuchi Gulati
Supplementary Figure 6. Comparison of outcomes between patients that were p16 positive vs. negative A) Progression-free survival and B) Overall survival comparison
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d562fb8bed14c80d7be0e121e927f7f
https://doi.org/10.1158/1078-0432.22551885
https://doi.org/10.1158/1078-0432.22551885